Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDAMA Off-Label Provisions Make FDA Sole Arbiter Of Scientific Data - WLF

Executive Summary

Provisions in the FDA Modernization Act of 1997 make the agency the sole arbiter of scientific merit, the Washington Legal Foundation stated in an April 29 brief filed in the WLF v. Henney case concerning off-label information dissemination.

You may also be interested in...



FDA Misgivings About Reprints Would Not Make Them "False" - WLF Lawyer

FDA will not be permitted to object to off-label reprints as "false and misleading" when the agency finds technical problems with an article, attorney Daniel Troy (Wiley, Rein & Fielding) asserted at an Aug. 18 Washington Legal Foundation forum on the impact of the recent WLF v. Henney off-label information dissemination ruling.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
UsernamePublicRestriction

Register

PS034123

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel